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Abstract 
Objective: the  RaInbow  survey  is  a  multinational
observational study assessing the tolerability and effi-
cacy  of  ritonavir-boosted  saquinavir  (Sqv/r),  using
the 500 mg film-coated Sqv formulation, in routine
clinical practice. this analysis presents data from the
german subgroup of protease inhibitor (PI)-pretreat-
ed, but Sqv-na￯ve patients.
Methods: Multicenter, prospective, open-label, 48 week
cohort study. Efficacy assessments included the pro-
portion of patients with HIv-1 Rna <50 and <400
copies/ml and changes in cd4 cell count from base-
line  to  week  48.  tolerability  assessments  included
changes in liver enzymes and lipid levels from baseline
to week 48. 
Results: a total of 426 patients were included in the
analysis. the proportion of patients with HIv Rna
levels <50 copies/ml at week 48 was 60.3 % (com-
pared with 31.7% at switch to Sqv/r) (intent-to-treat,
last  observation  carried  forward  analysis).  after  48
weeks,  median  cd4  count  increased  by  +61
cells/mm3 from baseline (p<0.01) and 60.3% of pa-
tients achieved HIv-1 Rna <50 copies/ml. Median
changes in fasting triglyceride levels (stratified accord-
ing  to  baseline  level)  at  week  48  were:  +14  mg/dl
(IqR  -8;  57)  for  patients  with  baseline  triglyceride
<200 mg/dl; -50 mg/dl (IqR -139; 0) for baseline
triglyceride 200–750 mg/dl, and -656 mg/dl (IqR -
1024; 0) for baseline triglyceride >750 mg/dl (p<0.01
for  all).  Median  changes  in  fasting  total  cholesterol
(tc) levels (stratified according to baseline) were +16
mg/dl  (IqR  -3;  43)  for  patients  with  baseline  tc
<200 mg/dl (p<0.01), -3 mg/dl (IqR -25; 25) for
baseline tc 200–300 mg/dl (p = 0.4), and -47 mg/dl
(IqR -87; -4) for baseline tc >300 mg/dl (p<0.01).
no significant changes in liver enzymes or bilirubin
were  observed.  Sqv  treatment  was  discontinued  in
22% of patients, 6% due to side effects.
Conclusions: these data confirm the efficacy and toler-
ability  of  Sqv/r  in  PI-experienced,  Sqv-na￯ve  pa-
tients treated in a real-life clinical setting. of particular
relevance  are  the  improvements  in  triglycerides  and
tc levels observed in patients with baseline grade III-
Iv elevations.
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IntRoductIon
the development of metabolic alterations such as dys-
lipidemia  and  body  fat  changes  (lipodystrophy)  is  a
major  consideration  with  the  use  of  protease  in-
hibitors (PIs) as part of Highly active anti-Retroviral
therapy (HaaRt) [1]. the link between HaaRt and
increased risk of cardiovascular disease was confirmed
almost a decade ago [2], and increased exposure to PIs
in particular has been associated with an increased risk
of myocardial infarction, which is partly explained by
dyslipidemia [3]. treatment with PIs is associated with
significantly increased levels of triglycerides, total cho-
lesterol  (tc),  low-density  lipoproteins  (ldl)  and
high-density lipoproteins (Hdl), as well as changes in
body fat [4]. lipid alterations and morphologic abnor-
malities vary between the different PIs; for example,
indinavir  has  been  associated  with  insulin  resistance
[5], and ritonavir-boosted lopinavir with hypertriglyc-
eridemia  and  hypercholesterolemia  [6],  whereas
atazanavir has been reported to have a relatively favor-
able lipid profile [7]. there are also differences in the
reported efficacy and tolerability of PIs and therefore
selecting  and  switching  treatment  regimens  in  those
patients with virological failure, toxicity, or changes in
lipid profiles related to a particular PI represents an
important management issue. 
Saquinavir (Inviraseﾮ, Sqv) is a potent inhibitor of
HIv-1  viral  protease,  which,  when  co-administered
with ritonavir boosting (Sqv/r) has been shown to be
effective in clinical trials of treatment-na￯ve and treat-
ment-experienced patients and to be associated with a
more  favorable  lipid  profile  than  ritonavir-boosted
lopinavir and indinavir, with improved tolerability [8-
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ed for initial PI-based aRt by international HIv treat-
ment guidelines [12-15]. Initially available as 200 mg
hard capsules, Sqv is now available as a 500 mg film-
coated tablet formulation which achieves the current
recommended  daily  dose  (1000  mg  twice  daily  with
100 mg ritonavir twice daily [16]) with a reduced pill
burden and simplified dosing [17]. although there is
currently  wide  treatment  experience  with  various
Sqv/ritonavir  combinations  and  with  the  previous
Sqv formulations, available data on the 500 mg film-
coated tablets is yet limited. 
the international RaInbow survey was designed
to identify a cohort of HIv-1 infected patients who
initiated  treatment  with,  500mg  film-coated  Sqv-
tablet in routine clinical practice. the survey aimed to
include  a  wide  cross-section  of  patient  populations,
including  aRt-na￯ve  patients  and  aRt–experienced
patients with a range of pretreatment histories. In this
analysis we present the final 48-week efficacy and tol-
erability data from patients who were previously treat-
ed with one or more PIs (PI-experienced), but who
were  Sqv-  na￯ve,  from  the  german  RaInbow 
coHoRt.
MatERIalS and MEtHodS
dESIgn
the  RaInbow  coHoRt  was  a  multicenter,  pro  -
spective,  non-interventional  48  week  observational
study in HIv-patients treated with Sqv 500 mg film-
coated tablets as part of their antiretroviral regimen
and took place between July 2005 and May 2008. 
Inclusion criteria for RaInbow were documented
HIv-1  infection  and  initiation  of  treatment  with
Sqv/ritonavir  (Sqv/r)  utilizing  the  500  mg  film-
coated  Sqv  tablet,  in  combination  with  other  anti-
retrovirals  as  part  of  routine  antiretroviral  therapy
(aRt). 
Patient selection for Sqv-based antiretroviral treat-
ment was at the discretion of the treating physician,
and the decision was made in accordance with the dec-
laration  of  Helsinki  and  with  german  treatment
guidelines,  published  by  the  german  aIdS-society
[15]. Patients were included in the RaInbow co-
HoRt  if  they  had  been  previously  treated  with  PI
containing  regimens,  but  that  did  not  include  Sqv.
there were no specified exclusion criteria, and no re-
strictions on the use of concomitant medication. In
order to avoid selection bias, all investigators were en-
couraged  to  report  data  from  all  eligible  patients  at
their  site  rather  than  reporting  on  a  random  subset
only. for patients who discontinued Sqv/r treatment
or with missing data, the last recorded values were car-
ried forward for inclusion in the final analysis (up to
week 48). 
the following demographic/baseline characteristic
data were collected: date of birth; ethnicity; gender;
height; weight; previous diseases; HIv risk exposure;
year of diagnosis; presumed mode of infection; cur-
rent disease stage; HIv-Rna viral load and cd4+ cell
count prior to starting boosted Sqv treatment; anti-
retroviral drug history; concomitant medications, in-
cluding any lipid lowering and antidiarrhetic medica-
tions; and hematology and biochemistry laboratory re-
sults, including blood where available.
Efficacy  and  tolerability  data  were  collected  from
the patient records and recorded on a central database
using identifying numbers only. Patient visits were al-
located to applicable windows: week 2–6, week 8–16,
week 20–28, week 32–40, and week 44–52. the fol-
lowing  data  were  recorded  from  the  patient  charts:
cd4+ cell count; HIv-Rna viral load; date of HIv-
Rna viral load and cd4+ cell count; HIv-Rna assay
used;  lower  limit  of  HIv-Rna  assay  used;  weight;
changes  in  background  antiretroviral  drugs;  changes
to/introduction  of  lipid  lowering  medications,  an-
tidiarrhetic medication and other concomitant medica-
tion; unexpected clinical adverse events; treatment ad-
herence information and reason of premature with-
drawal;  hematology  and  biochemistry  laboratory  re-
sults (including fasting blood lipids).
EndPoIntS
tolerability endpoints were: changes in fasting lipids
levels (total cholesterol [tc], high-density lipoprotein
[Hdl] and low-density lipoprotein [ldl] cholesterol,
and triglycerides) from baseline to week 48 stratified
according to baseline levels; changes in liver enzymes
(alanine  aminotransferase  [alt],  aspartame  amino-
transferase  [aSt],  and  gamma  glutamyl  transferase
[ggt]);  and  frequency  of  grade  3  and  4  adverse
events  or  death,  including  those  considered  by  the
treating physician to be related to Sqv. 
Efficacy endpoints were: percentage of patients with
HIv-Rna<50  copies/ml  at  week  48;  percentage  of
patients with HIv-Rna <400 copies/ml at week 48;
and change in cd4 cell count from baseline at week 48. 
StatIStIcS
all PI-experienced, Sqv-na￯ve patients included in the
RaInbow  coHoRt  with  complete  baseline  visit
were included in the analysis.  Reflecting the observa-
tional nature of the study, we used an intent-to-treat
(Itt)  analysis  of  last  observation  carried  forward
(locf) i.e. missing values for HIv-Rna and cd4+
cell count values, lipids and liver enzymes were taken
as the previous observed value. 
descriptive  summary  statistics  were  used  for  this
cohort analysis, characterizing changes in cd4+ cell
count and HIv-Rna from baseline, the type and fre-
quency  of  adverse  events  observed,  and  changes  in
safety relevant laboratory parameters. for continuous
variables the following statistics were calculated: mean;
standard deviation, median, inter-quartile range (IqR)
and  minimum  and  maximum  values.  for  categorical
variables, number of values in each category and per-
centageof the values with regard to number of patients
in  the  study  population  were  calculated.  Explorative
statistical methods were used with regard to the effica-
cy endpoints and changes in safety-relevant laboratory
parameters.  changes  from  baseline  were  tested  for 
significance using the wilcoxon signed rank test. Shifts
in ranking of baseline values and week 48 values were
assessed  using  Shift  tables  and  Mcnemar/bowker
tests.
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between July 2005 and february 2007, 1,669 patients
overall were enrolled in the german RaInbow co-
HoRt. baseline data were missing for 120 patients,
leaving 1,549 patients from 66 centers with evaluable
data. of these, 669 patients received Sqv as part of
their  antiretroviral  regimen  before  switching  to  the
Sqv 500 mg film-coated tablet and so were excluded
from the current analysis. the remaining 880 patients
were Sqv-na￯ve. of these, 454 patients were PI-na￯ve
and were not included in the current analysis. In all,
426 patients were PI-experienced but Sqv-na￯ve and
met the criteria for evaluation in this analysis. baseline
characteristics and demographics of these patients are
shown in table 1.
the majority of patients was male, caucasian, with a
median age of 43 years and men who reported sex with
men (MSM) as primary risk of HIv transmission. the
median number of previous aRt regimens was 4, and
patients had been treated with a median of 2 PIs. de-
tails of previous aRt regimens are shown in table 2. 
the most commonly previously used aRt regimen
was a PI in combination with nRtI/nnRtI (55%)
and the PI most commonly used in previous regimens
was  lopinavir/ritonavir  (lPv/r)  in  30%  of  patients.
of all, the main reason to switch to Sqv/r was viro-
logical failure (n = 182 patients or 42.7%), followed by
previous antiretroviral regimen intolerance (n = 91 pa-
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Table  1. baseline  characteristics  and  demographics.  MSM:
Men who have sex with men; cdc: center for disease con-
trol;  IqR:  Interquartile  range;  aRt:  antiretroviral  therapy;
PI: Protease inhibitor.
PI-experienced, but SQV-na￯ve patients n = 426
Male, % (n) 84 (359)
age in years, median (IqR) 43 (37; 49)
Height in cm, median, (IqR) 177 (172; 182)
weight in kg, median (IqR) 72 (65; 80)
Hepatitis b, % (n) 5 (21)
Hepatitis c, % (n) 12 (50)
Infection mode, %
MSM 62
Heterosexual 15
Ivdu 7
not specified 16
Race, %
caucasian 84
african 8
asian 3
not specified 5
CDC stage, %
a 17
b 43
c 38
not specified 2
time since first diagnosis in years, median  9 (4; 14)
(IqR)
time since first aRt in years, median  7.3 (3.4; 9.4)
(IqR)
number of previous regimen, median  4 (3; ≥6)
(IqR)
number of previous PIs, median (IqR) 2 (1; 3)
treatment interruption before start of  21 (91)
new regimen, % (n)
duration of treatment interruption in  8.8 (3; 23)
months,  median (IqR)
HIv Rna (copies/ml), median (IqR) 599 (<50; 31,291)
Proportion of patients with HIv Rna  31.7%
<50 copies/ml at baseline
cd4-count (cells/mm3) median (IqR) 320 (177; 506)
Table  2. Previous antiretroviral regimen. nRtI: nucleoside
reverse  transcriptase  inhibitor;  nnRtI:  non-nucleoside  re-
verse  transcriptase  inhibitors;  PI:  protease  inhibitor;  lPv:
lopinavir; atv: atazanavir; faP: fosamprenavir; r: ritonavir-
boosted.
Regimen n%
≥3 NRTI 47 11
NNRTI + NRTI 61 14
PI/r + NRTI/NNRTI 236 55
lPv/r 111 26
atv/r 51 12
faP/r 34 8
Double PI 23 5
lPv/atv/r   11 3
lPv/faP/r 51
Not specified 46 11
Other 13 3
Table 3. antiviral drugs included in Sqv/ritonavir regimens
nRtI:  nucleoside  reverse  transcriptase  inhibitor;  nnRtI:
non-nucleoside reverse transcriptase inhibitors; PI: protease
inhibitor; tdf: tenofovir; ftc: emtricitabine; aZt: zidovu-
dine; 3tc: lamivudine; abc: abacavir; lPv: lopinavir; atv:
atazanavir; faP: fosamprenavir.
n%
2 NRTI 178 42
tdf/ftc 103 24
aZt/3tc 31 7
3tc/abc 20 5
PI 131 31
lPv 76 18
atv 39 9
faP 15 4
PI + NRTI/NNRTI 58 14
lPv   34 8
atv 15 4
faP 72
Not specified 20
Other 57 13
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patient  was  possible.  details  of  other  antiretroviral
drugs used with Sqv/r in this analysis are shown in
table 3. 
the majority of patients received Sqv/r either as
part of a PI plus two nRtIs regimen, most commonly
tdf and ftc, or as a double PI regimen, most com-
monly with lPv.
dIScontInuatIonS
In total, 22% (94/426) of the patients withdrew from
the study prior to week 48 (3.3% by week 4; 4.2%
week 4-12; 6.3% week 12-24; 4.0% week 24-36; 4.2%
week 36-48). Reasons for discontinuations were: side
effects (5.5%; n = 24), virological failure (3.5%; n =
15), lost to follow up (4%; n = 18), lack of adherence
(3.5%; n = 15), intercurrent disease (1%; n = 3) and
death  (0.5  %;  n  =  2;  all  classified  as  unrelated  to
Sqv).  Reasons  discontinuations  were  not  specified
for 17 patients (4%). of the 15 patients who with-
drew from study due to virological failure, resistance
data  prior  to  the  switch  to  the  Sqv-based  regimen
were available for eight patients, and resistance against
a  median  of  3  (0;  6)  protease  inhibitors  was  docu-
mented. no resistance data were available for the  re-
maining seven patients.
SafEty and tolERabIlIty
based on the reports obtained in the analysis, there
were 34 adverse events (aEs) assessed as grade 3 or 4
and considered to be, in the opinion of the treating
physician, possibly or likely related to Sqv/r. the ma-
jority  of  events  were  diarrhea  and  gastrointestinal
problems, as recorded in 18 patients (4.2%) (table 4).
treatment  with  antidiarrhea  agents  (13.0%)  reduced
the incidence of aEs.
there  were  no  clinically  relevant  changes  from
baseline  in  liver  enzyme  or  bilirubin  levels  at  week 
48. Median changes from baseline to week 48 in fe-
male patients were: alt -3.0 u/l (IqR -10.0, 4.0; n
= 55); aSt -2.0 u/l (IqR -7.0 , 6.0; n = 47); ggt
5.0 u/l (IqR -2 , 45.6; n = 54) (Itt, locf analysis).
In  male  patients,  median  changes  from  baseline  to
week  48  were:  alt  0.0  u/l  (IqR  -8.0  ,  6.0;  n  = 
335); aSt 0.0 u/l (IqR -6.0 , 5.0; n = 301); ggt -
8.15 u/l (IqR -0.55 , 393; n = 332) (Itt, locf
analysis). Median change in bilirubin levels from base-
line to week 48 was 0.0 mg/dl (IqR -0.2, 0.25; n =
258).
vIRologIcal and IMMunologIcal RESPonSE
Median increase in cd4 count was + 61 cells/mm3
(IqR -9; 170; p<0.01) from baseline to week 48 (fig.
3). the proportion of patients achieving HIv Rna
levels  of  <50  copies/ml  by  48  weeks  was  60.3  %
(compared with 31.7% at baseline) and 74.9 % (com-
pared  with  44.8%  at  baseline)  for  <400  copies/ml
(Itt, locf analysis), respectively (fig. 3). 
In patients who switched to Sqv because of toxici-
ty to another PI, HIv-Rna and cd4 levels remained
stable. for those patients who switched to Sqv be-
cause of virological failure, there was a marked im-
provement in these parameters.
cHangES In lIPId PRofIlES
there was no significant change in overall triglyceride
levels between baseline and week 48 in our patient co-
hort (p = 0.81; Mcnemar/bowker testing). However
when stratified according to baseline triglyceride lev-
els, patients with baseline triglyceride above 200–750
mg/dl and, most markedly, those above 750 mg/dl
showed  significant  decreases  in  levels  (figs.  1a  and
1b). Median changes in triglyceride levels stratified ac-
cording to baseline levels were +14 mg/dl (IqR -8;
57) for patients with baseline <200 mg/dl (p<0.01; n
= 196), -50 mg/dl (IqR -139; 0) for patients with
baseline 200–750 mg/dl (p<0.01; n = 136) and -656
mg/dl (IqR -1024; 0) for patients with baseline >750
mg/dl (p<0.01; n = 15) (Itt, locf analysis). 
In the overall cohort there was slight but significant
shift towards higher total cholesterol (tc) levels be-
tween baseline and week 48 in the Mcnemar/bowker
test  (p  =  0.026).  However,  after  patients  had  been
stratified according to baseline tc levels, a modest in-
crease in median tc levels of +16 mg/dl (IqR -3;
43)  for  patients  with  baseline  levels  <200  mg/dl
(p<0.01; n = 206), a decrease of -3 mg/dl (IqR -25;
25) for patients with baseline levels 200–300 mg/dl (p
=  0.40;  n  =  121)  and  a  marked  fall  of  -47  mg/dl
(IqR –87; -4) for patients with baseline levels >300
mg/dl (p<0.01; n = 11) (Itt, locf analysis) was
observed (figs. 2 and 2b). 
with regard to ldl levels, although in the cohort
of patients as a whole there was a significant shift to-
wards an increase in ldl levels between baseline and
week  48  in  the  Mcnemar/bowker  test  (p  =  0.01),
only  patients  with  ldl  <130  mg/dl  at  baseline
showed a small increase in ldl cholesterol at week
48 (+8 mg/dl [IqR -4; 27]; p<0.01; n = 146) there
was no overall change in levels for patients with ldl
130–190 mg/dl at baseline (0 mg/dl [IqR -15; 14];
p = 0.79; n = 66), while levels fell significantly in pa-
tients with ldl >190 mg/dl at baseline (-41 mg/dl
[IqR -49; 6]; p<0.05; n = 9) (Itt, locf analysis)
(fig. 2a). 
there was also a small, but non-significant increase
in Hdl levels between baseline and week 48 in the
group of patients as a whole by the bowker test (p =
0.13) (data not shown). when stratified according to
baseline, this was significant in patients with Hdl ≥
40 mg/dl at baseline (+ 5 mg/dl [IqR 0; 9]; p = 0.01;
n = 93).
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Table 4. adverse events (aEs) related to Sqv
Number  Number  %
of AEs of patients
All AEs 43 25 5.9
AEs Grade 3/4 34 18 4.2
diarrhoea 12
gastrointestinal system  16
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a
b
Fig. 1. change in triglyceride levels from base-
line  to  week  48  (Itt,  locf):  (a)  median
change (IqR) of triglycerides from baseline to
week 48, stratified according to baseline level;
(b)  changes  in  triglyceride  levels  stratified  by
grade.
baseline strata
normal:  <200  mg/dl;  grade  I-II:  200–750
mg/dl; grade III-Iv: >750 mg/dl
b
Fig.  2.  change  in  total  cholesterol  and  ldl
from baseline to week 48 (Itt, locf): (a) me-
dian  change  (IqR)  in  total  cholesterol  and
ldl, stratified according to baseline level; (b)
changes in total cholesterol stratified by grade.
baseline strata
normal: total cholesterol <200 mg/dl; ldl
<130 mg/dl
grade I-II: total cholesterol 200–300 mg/dl;
ldl 130–190 mg/dl
grade III-Iv: total cholesterol >300 mg/dl;
ldl >190 mg/dl
a
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agents  remained  stable  throughout  the  study  period
(6.6 % at baseline vs. 6.1 %, 6.3 %, 5.9 % and 6.3 % at
weeks 12, 24, 36 and 48, respectively).
the following parameters did not affect outcome in
terms of lipid levels: use of lipid-lowering agents; pre-
vious treatment with stavudine or efavirenz; previous
therapy using double PIs; new use of Sqv in double
PI therapy.
dIScuSSIon
this analysis confirms that ritonavir-boosted Sqv is
effective  and  well-tolerated  in  PI-experienced  but
Sqv-na￯ve patients in a real-life clinical setting. our
data demonstrate that switching to Sqv was beneficial
both for those patients who had intolerance or toxicity
to their previous aRt regimen, and those who failed
previous treatment due to virological failure. the pro-
portion  of  patients  with  HIv  Rna  levels  <50
copies/ml at 48 weeks was almost twice that seen at
baseline, and a significant increase in cd4 cell count
was also seen by 48 weeks. Interestingly, the increase
in cd4 count reflected the virological response. In-
creases in cd4 count and reductions in HIv-1 Rna
levels  were  especially  marked  in  those  patients  who
switched to Sqv because of previous virological fail-
ure. In PI-experienced patients with grade 3/4 eleva-
tions in lipid levels at baseline, switching treatment to
Sqv was associated with significant and marked im-
provements in triglyceride, ldl cholesterol and tc
levels. overall, lipid level changes after 48 weeks of
Sqv-based aRt were relatively small in those patients
with  normal  baseline  levels,  but  median  levels  were
significantly  improved  in  those  patients  with  grade
3/4  levels  at  baseline.  of  note,  median  triglyceride
levels in PI-pretreated patients with grade 3/4 levels
showed a particularly marked decline. the favorable
triglyceride, lipid and liver enzyme and bilirubin pro-
files  confirm  the  tolerability  of  Sqv  500  mg  film
tablets in this group of patients. 
the  tolerability  and  efficacy  of  Sqv/r  1000/100
mg bid has been demonstrated in the a number of tri-
als, which incorporated a range of patient types in-
cluding patients who switched to Sqv/r as a result of
intolerance  or  virological  failure  [8,12,18,19].  these
studies predominantly used the earlier 200 mg hard-
capsule or soft gel formulations of Sqv. the 500 mg
film-coated formulation of Sqv used in our study was
introduced to address the problems of high pill bur-
den and its potential effect on adherence [17]. as there
are currently few data from studies using the new for-
mulation in PI-experienced patients, we conducted the
current analysis to investigate the safety and efficacy
of the 500 mg film-coated formulation of Sqv in this
patient population treated in a real-life clinical setting.
Interestingly,  results  from  our  cohort  of  PI-experi-
enced patients are similar to those seen in aRt-na￯ve
patients.  In  the  open-label,  non-inferiority  gEMInI
trial of first-line Sqv/r plus emtricitabine/tenefovir
(ftc/tdf)  vs.  ritonavir-bosted  lopinavir  (lPv/r)
plus ftc/tdf, 64.7% and 72.5% of patients in the
Sqv/r  arm  achieved  HIv-1  Rna  levels  <50
copies/ml  and  <400  copies/ml,  respectively  [11],
compared with 60.3% and 74.9%, respectively, in the
current analysis.  
the incidence and nature of aEs were similar in
our cohort of patients to those previously reported in
clinical trials and were most commonly gastrointestinal
and diarrhea [8,9,11,18]. there was no indication of
relevant changes in liver enzymes or bilirubin in our
patient cohort. changes in lipid profile are of particu-
lar concern with PI-based aRt, with treatment-related
dyslipidemia  being  linked  to  atherogenesis  and  in-
creased risk of coronary artery disease [1-4].  treat-
ment  with  Sqv/r  has  been  found  to  be  associated
with  a  more  favorable  lipid  profile  than  ritonavir-
boosted indinavir and lopinavir [8, 11].  In the current
analysis, switching to Sqv/r resulted in a marked de-
crease in levels of both triglycerides and total choles-
terol in those patients who had increased baseline lev-
els, most markedly in those with grade III/Iv levels
at baseline. furthermore, ldl cholesterol levels also
declined in those patients with high baseline levels in
our  analysis.  despite  a  slight  increase  in  median
triglyceride-,  total  cholesterol-  and  ldl  cholesterol-
levels in patients within the normal range at baseline,
the whole proportion of patients within the normal
range for these parameters was comparable high, pre-
and post-Sqv/r therapy. taken together, these finding
suggest a favorable lipid profile of Sqv/r for PI-ex-
perienced patients.
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Fig. 3. Proportion of patients with
HIv-1 Rna levels <50 copies/ml
and <400 copies/ml and change
in  cd4+  levels  baseline  to  week
48 (Itt, locf).
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tients from the RaInbow survey lies in the fact that
it consists of an unselected cohort of HIv-infected
patients treated under routine, ‘real-life’ conditions in
contrast  to  the  highly  selective  and  controlled  ran-
domised  trial  situation.  the  data  derived  from  such
cohorts may more closely reflect clinical practice than
results obtained from the optimized setting of clinical
studies. However the study has the usual limitations of
observational analyses. It is not possible to rule out se-
lection  bias,  although  all  RaInbow  investigators
were encouraged to report data from all eligible pa-
tients at their site rather than reporting on a random
subset only. In addition, the case-payment system used
for data collection was based on completed visits per
case, which may also have encouraged reporting.
this cohort study adds to the efficacy and safety
data available for the new formulation of Sqv used at
the  recommended  treatment  dose  with  ritonavir
boosting by investigating its tolerability and effective-
ness  in  PI-experienced  patients.  In  addition  it  con-
firms the efficacy and tolerability of Sqv seen in clin-
ical trials in the ‘real-world’ clinical setting. based on
the findings of this analysis, Sqv/r offers a viable op-
tion both for patients who have virological failure on
previous PI-based therapy, or who suffer toxicity. In
particular,  in  those  patients  with  markedly  elevated
lipid levels following PI treatment, a switch to Sqv/r
was associated with a marked decline in triglyceride,
total cholesterol and ldl cholesterol.
In conclusion, results from this observational co-
hort of PI-experienced patients treated with the cur-
rently approved dose of Sqv/r and using the 500 mg
film-coated Sqv formulation in the ‘real life’ clinical
setting are consistent with high efficacy and tolerabili-
ty seen in controlled studies with Sqv/r.
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